Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Azaibi Tamin is active.

Publication


Featured researches published by Azaibi Tamin.


Microbes and Infection | 2001

Molecular biology of Hendra and Nipah viruses

Lin-Fa Wang; Brian H. Harcourt; Meng Yu; Azaibi Tamin; Paul A. Rota; William J. Bellini; Bryan T. Eaton

The structure and genetic organization of Hendra and Nipah viruses places them in the subfamily Paramyxovirinae. However, low homology with other subfamily members and several novel biological and molecular features such as genome length and F(0 )cleavage site suggest classification in a new genus within the Paramyxovirinae.


The Lancet | 2003

Effects of a SARS-associated coronavirus vaccine in monkeys

Wentao Gao; Azaibi Tamin; Adam C. Soloff; Leonardo D'Aiuto; Edward Nwanegbo; Paul D. Robbins; William J. Bellini; Simon M. Barratt-Boyes; Andrea Gambotto

Summary The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.


Emerging Infectious Diseases | 2005

Genetic Characterization of Nipah Virus, Bangladesh, 2004

Brian H. Harcourt; Luis Lowe; Azaibi Tamin; Xin Liu; Bettina Bankamp; Nadine Bowden; Pierre E. Rollin; James A. Comer; Thomas G. Ksiazek; Mohammed Jahangir Hossain; Robert F. Breiman; William J. Bellini; Paul A. Rota

Until 2004, identification of Nipah virus (NV)-like outbreaks in Bangladesh was based on serology. We describe the genetic characterization of a new strain of NV isolated during outbreaks in Bangladesh (NV-B) in 2004, which confirms that NV was the etiologic agent responsible for these outbreaks.


Virus Research | 1998

NEW GENETIC GROUP OF MEASLES VIRUS ISOLATED IN THE PEOPLE'S REPUBLIC OF CHINA

Wenbo Xu; Azaibi Tamin; Jennifer S. Rota; LiBi Zhang; William J. Bellini; Paul A. Rota

Genetic and antigenic characterization of 14 wild-type measles viruses isolated from four provinces in the Peoples Republic of China during 1993 and 1994 was conducted. Sequence analyses of the hemagglutinin (H) and nucleoprotein (N) genes indicated that 13 of the 14 Chinese viruses comprised a previously undescribed genetic group. Viruses from this unique group were the most genetically diverse measles viruses described, so far. The Chinese viruses differed from other wild-type viruses by as much as 6.9% in the H gene and 7.0% in the N gene at the nucleotide level. One of the 14 viruses was a member of the same genetic group that contains the Edmonston strain. Antigenic analysis using monoclonal antibodies to the H protein did not detect significant differences in binding patterns between the Chinese viruses and other wild-type measles viruses. In addition, representative viruses from the unique Chinese group were neutralized by both human post-vaccination antiserum and mouse antiserum against the H protein of the Edmonston vaccine virus. Viruses closely related to these Chinese viruses were also associated with importations of measles into the United States during 1997 from Vietnam and Hong Kong suggesting that viruses from this new genetic group continue to circulate in China and possibly other parts of Asia.


The Journal of Infectious Diseases | 2011

Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals.

Carole J. Hickman; Terri B. Hyde; Sun Bae Sowers; Sara Mercader; Marcia McGrew; Nobia Williams; Judy A. Beeler; Susette Audet; Bryan Kiehl; Robin Nandy; Azaibi Tamin; William J. Bellini

Waning immunity or secondary vaccine failure (SVF) has been anticipated by some as a challenge to global measles elimination efforts. Although such cases are infrequent, measles virus (MeV) infection can occur in vaccinated individuals following intense and/or prolonged exposure to an infected individual and may present as a modified illness that is unrecognizable as measles outside of the context of a measles outbreak. The immunoglobulin M response in previously vaccinated individuals may be nominal or fleeting, and viral replication may be limited. As global elimination proceeds, additional methods for confirming modified measles cases may be needed to understand whether SVF cases contribute to continued measles virus (MeV) transmission. In this report, we describe clinical symptoms and laboratory results for unvaccinated individuals with acute measles and individuals with SVF identified during MeV outbreaks. SVF cases were characterized by the serological parameters of high-avidity antibodies and distinctively high levels of neutralizing antibody. These parameters may represent useful biomarkers for classification of SVF cases that previously could not be confirmed as such using routine laboratory diagnostic techniques.


Vaccine | 2008

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.

Matthias Liniger; Armando Zuniga; Azaibi Tamin; Teldja N. Azzouz-Morin; Marlyse Knuchel; René R. Marty; Marian Wiegand; Sara Weibel; David J. Kelvin; Paul A. Rota; Hussein Y. Naim

Summary Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.


Journal of General Virology | 2009

Determination of the henipavirus phosphoprotein gene mRNA editing frequencies and detection of the C, V and W proteins of Nipah virus in virus-infected cells.

Michael K. Lo; Brian H. Harcourt; Bruce A. Mungall; Azaibi Tamin; Mark E. Peeples; William J. Bellini; Paul A. Rota

The henipaviruses, Nipah virus (NiV) and Hendra virus (HeV), are highly pathogenic zoonotic paramyxoviruses. Like many other paramyxoviruses, henipaviruses employ a process of co-transcriptional mRNA editing during transcription of the phosphoprotein (P) gene to generate additional mRNAs encoding the V and W proteins. The C protein is translated from the P mRNA, but in an alternate reading frame. Sequence analysis of multiple, cloned mRNAs showed that the mRNA editing frequencies of the P genes of the henipaviruses are higher than those reported for other paramyxoviruses. Antisera to synthetic peptides from the P, V, W and C proteins of NiV were generated to study their expression in infected cells. All proteins were detected in both infected cells and purified virions. In infected cells, the W protein was detected in the nucleus while P, V and C were found in the cytoplasm.


Journal of Virological Methods | 2009

Development of a Neutralization Assay for Nipah Virus Using Pseudotype Particles

Azaibi Tamin; Brian H. Harcourt; Michael K. Lo; James A. Roth; Mike C. Wolf; Benhur Lee; Hana Weingartl; Jean-Christophe Audonnet; William J. Bellini; Paul A. Rota

Nipah virus (NiV) and Hendra virus (HeV) are zoonotic paramyxoviruses capable of causing severe disease in humans and animals. These viruses require biosafety level 4 (BSL-4) containment. Like other paramyxoviruses, the plaque reduction neutralization test (PRNT) can be used to detect antibodies to the surface glycoproteins, fusion (F) and attachment (G), and PRNT titers give an indication of protective immunity. Unfortunately, for NiV and HeV, the PRNT must be performed in BSL-4 containment and takes several days to complete. Thus, we have developed a neutralization assay using VSV pseudotype particles expressing the F and G proteins of NiV (pVSV-NiV-F/G) as target antigens. This rapid assay, which can be performed at BSL-2, was evaluated using serum samples from outbreak investigations and more than 300 serum samples from an experimental NiV vaccination study in swine. The results of the neutralization assays with pVSV-NiV-F/G as antigen showed a good correlation with those of standard PRNT. Therefore, this new method has the potential to be a rapid and cost-effective diagnostic method, especially in locations that lack high containment facilities, and will provide a valuable tool for basic research and vaccine development.


Virus Research | 2005

SARS-coronavirus replication in human peripheral monocytes/macrophages

Mamadi Yilla; Brian H. Harcourt; Carole J. Hickman; Marcia McGrew; Azaibi Tamin; Cynthia S. Goldsmith; William J. Bellini; Larry J. Anderson

Abstract A novel coronavirus (CoV) has been described in association with cases of severe acute respiratory syndrome (SARS). The virus, SARS-CoV, differs from the previously described human coronaviruses, 229E and OC43. 229E was previously shown to productively infect human monocytes/macrophages, whereas OC43 poorly infected the cells. In this study, we examined whether SARS-CoV could productively infect purified monocytes/macrophages (PM) derived from human donor cells. Unlike 229E-infected cells, which produced viral titers of 103.5 to 106 TCID50/ml, SARS-CoV replicated poorly in PM, producing titers of 101.75 to 102 TCID50/ml. This finding was similar to results reported for OC43-infected cells, with titers ranging from 101.2 to 102.7 TCID50/ml. Of interest, SARS-CoV proteins were detected only in PM that did not produce significant amounts of interferon (IFN)-α, and in one such case, preliminary electron microscope studies demonstrated that SARS-CoV-like particles could enter the cells, possibly via phagocytosis. These results suggest that SARS-CoV, like human CoV OC43, poorly infects human PM, and production of IFN-α by these cells further limits the infection. Given the importance of monocytes/macrophages to the immune response, it is possible that their infection by SARS-CoV and alteration of this infection by IFN-α may be important to the course of the infection in humans.


PLOS Pathogens | 2008

Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway.

Jianhua Sui; Daniel Aird; Azaibi Tamin; Akikazu Murakami; Meiying Yan; Anuradha Yammanuru; Huaiqi Jing; Biao Kan; Xin Liu; Quan Zhu; Qing-An Yuan; Gregory P. Adams; William J. Bellini; Jianguo Xu; Larry J. Anderson; Wayne A. Marasco

Phylogenetic analyses have provided strong evidence that amino acid changes in spike (S) protein of animal and human SARS coronaviruses (SARS-CoVs) during and between two zoonotic transfers (2002/03 and 2003/04) are the result of positive selection. While several studies support that some amino acid changes between animal and human viruses are the result of inter-species adaptation, the role of neutralizing antibodies (nAbs) in driving SARS-CoV evolution, particularly during intra-species transmission, is unknown. A detailed examination of SARS-CoV infected animal and human convalescent sera could provide evidence of nAb pressure which, if found, may lead to strategies to effectively block virus evolution pathways by broadening the activity of nAbs. Here we show, by focusing on a dominant neutralization epitope, that contemporaneous- and cross-strain nAb responses against SARS-CoV spike protein exist during natural infection. In vitro immune pressure on this epitope using 2002/03 strain-specific nAb 80R recapitulated a dominant escape mutation that was present in all 2003/04 animal and human viruses. Strategies to block this nAb escape/naturally occurring evolution pathway by generating broad nAbs (BnAbs) with activity against 80R escape mutants and both 2002/03 and 2003/04 strains were explored. Structure-based amino acid changes in an activation-induced cytidine deaminase (AID) “hot spot” in a light chain CDR (complementarity determining region) alone, introduced through shuffling of naturally occurring non-immune human VL chain repertoire or by targeted mutagenesis, were successful in generating these BnAbs. These results demonstrate that nAb-mediated immune pressure is likely a driving force for positive selection during intra-species transmission of SARS-CoV. Somatic hypermutation (SHM) of a single VL CDR can markedly broaden the activity of a strain-specific nAb. The strategies investigated in this study, in particular the use of structural information in combination of chain-shuffling as well as hot-spot CDR mutagenesis, can be exploited to broaden neutralization activity, to improve anti-viral nAb therapies, and directly manipulate virus evolution.

Collaboration


Dive into the Azaibi Tamin's collaboration.

Top Co-Authors

Avatar

William J. Bellini

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Paul A. Rota

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Brian H. Harcourt

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Larry J. Anderson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Pierre E. Rollin

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Thomas G. Ksiazek

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Congrong Miao

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Jennifer L. Harcourt

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Lia M. Haynes

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Michael K. Lo

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge